|
gptkbp:instanceOf
|
gptkb:enantiomer
gptkb:drug
|
|
gptkbp:approvalYear
|
2019
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N01AX14
|
|
gptkbp:brand
|
gptkb:Ketanest
gptkb:Spravato
|
|
gptkbp:CASNumber
|
gptkb:33643-46-8
|
|
gptkbp:chemicalFormula
|
C13H16ClNO
|
|
gptkbp:chirality
|
S (sinister)
|
|
gptkbp:discoveredBy
|
gptkb:Calvin_Stevens
|
|
gptkbp:discoveredIn
|
1962
|
|
gptkbp:eliminationHalfLife
|
2.5-3 hours
|
|
gptkbp:isomerOf
|
R-ketamine
racemic ketamine
|
|
gptkbp:IUPACName
|
(S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:NMDA_receptor_antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2103837
182137
CHEBI:61375
|
|
gptkbp:routeOfAdministration
|
intramuscular
intravenous
nasal
|
|
gptkbp:sideEffect
|
gptkb:hallucination
nausea
dissociation
increased blood pressure
|
|
gptkbp:UNII
|
690G0D6V8H
|
|
gptkbp:usedFor
|
treatment-resistant depression
anesthesia
|
|
gptkbp:bfsParent
|
gptkb:Esketamine
|
|
gptkbp:bfsLayer
|
7
|
|
http://www.w3.org/2000/01/rdf-schema#label
|
S-ketamine
|